<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02318368</url>
  </required_header>
  <id_info>
    <org_study_id>AV-299-14-206</org_study_id>
    <nct_id>NCT02318368</nct_id>
  </id_info>
  <brief_title>A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label</brief_title>
  <acronym>FOCAL</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biodesix Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 multicenter, controlled, randomized, double-blind study to evaluate the efficacy and
      safety of ficlatuzumab versus placebo when administered with erlotinib in subjects with
      previously untreated metastatic EGFR-mutated NSCLC and BDX004 Positive Label.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival is defined as the time from the date of randomization to the date of the first objective documentation of radiographic disease progression or death due to any cause, whichever occurs first.</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival as measured from the date of randomization to the date of death.</measure>
    <time_frame>Approximately 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate is defined as a CR or PR according to RECIST v.1.1 recorded from randomization until disease progression or death due to any cause.</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate is defined as CR, PR, or SD at least 4 cycles (16 weeks) according to the RECIST v.1.1 recorded in the time period between randomization and disease progression or death to any cause.</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability, as defined by number of AEs.</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ficlatuzumab and erlotinib will be calculated from serum and plasma levels in the blood over time.</measure>
    <time_frame>Cycle 1 day 1 &amp; day 15, Cycle 2 day 1 &amp; day 15, Cycle 3 day 1 &amp; day 15, Cycle 4 day 1 &amp; day 15, Cycle 5 day 1, Cycle 7 day 1, Cycle 9 day 1, Cycle 11 day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Ficlatuzumab plus erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with 20 mg/kg Ficlatuzumab administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus erlotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with Placebo administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ficlatuzumab</intervention_name>
    <arm_group_label>Ficlatuzumab plus erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <arm_group_label>Ficlatuzumab plus erlotinib</arm_group_label>
    <arm_group_label>Placebo plus erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo plus erlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Histologically and/or cytologically confirmed primary diagnosis of Stage IV NSCLC
             (according to American Joint Committee on Cancer [AJCC] 7th edition lung cancer
             staging criteria).

          -  Measurable disease according to RECIST v.1.1.

          -  An EGFR exon 19 deletion and/or an exon 21 (L858R) substitution mutation.

          -  BDX004 Positive Label.

          -  Have received no prior systemic chemotherapy, immunotherapy, targeted therapy, or
             biologic therapy for metastatic NSCLC. Subjects may have previously been treated with
             postoperative adjuvant chemotherapy for early stage lung cancer or chemo radiotherapy
             for locally advanced disease provided this was completed at least 6 months prior to
             enrollment. No prior EGFR TKI therapy is allowed for any stage of NSCLC.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion
             Criteria

          -  History of severe allergic or anaphylactic reactions or hypersensitivity to
             recombinant proteins or excipients in the investigational agent or erlotinib.

          -  History of known brain metastases.

          -  Prior treatment with any other investigational drug or biologic agent within 5 half
             lives prior to randomization, or any investigational device within 2 weeks prior to
             randomization.

          -  Any unresolved toxicity from previous radiation therapy.

          -  Significant cardiovascular disease, including:

               -  Echocardiogram (ECHO) or multiple gated acquisition (MUGA) showing left
                  ventricular ejection fraction of less than 55%.

               -  Cardiac failure New York Heart Association class III or IV.

               -  Myocardial infarction, severe or unstable angina within 6 months prior to
                  randomization.

               -  History of serious ventricular arrhythmia (ie, ventricular tachycardia or
                  ventricular fibrillation).

               -  Significant thrombotic or embolic events within 3 months prior to randomization
                  (significant thrombotic or embolic events include but are not limited to stroke
                  or transient ischemic attack).

               -  Any uncontrolled or severe cardiovascular disease.

          -  History of prior malignancy within 3 years prior to randomization (except for
             adequately treated non-melanoma skin cancer, carcinoma in situ of the breast or
             cervix, superficial bladder cancer, or early stage prostate cancer, without evidence
             of recurrence).

          -  Radiographic evidence of interstitial lung disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael N Needle, MD</last_name>
    <role>Study Director</role>
    <affiliation>AVEO Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francis Payumo</last_name>
    <phone>617-531-8292</phone>
    <email>fpayumo@aveooncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristen Mills</last_name>
    <phone>617-588-1994</phone>
    <email>kmills@aveooncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSF Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Viola Zhu</last_name>
      <phone>559-256-9680</phone>
    </contact>
    <investigator>
      <last_name>Viola Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Lyudmila Bazenova</last_name>
      <phone>858-246-1093</phone>
    </contact>
    <investigator>
      <last_name>Lyudmila Bazhenova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakes Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Eloy Roman</last_name>
      <phone>786-362-5763</phone>
    </contact>
    <investigator>
      <last_name>Eloy Roman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Jennifer Carney</last_name>
      <phone>808-432-4689</phone>
    </contact>
    <investigator>
      <last_name>Jennifer Carney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Acadiana</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Salman Malad</last_name>
      <phone>337-289-8656</phone>
    </contact>
    <investigator>
      <last_name>Salman Malad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Julian Molina</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Julian Molina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queens Hospital Cancer Center</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Mary Kemeny</last_name>
      <phone>718-883-3751</phone>
    </contact>
    <investigator>
      <last_name>Mary Kemeny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Benjamin Levy</last_name>
      <phone>212-367-0190</phone>
    </contact>
    <investigator>
      <last_name>Benjamin Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Raza Khan</last_name>
      <phone>330-363-1250</phone>
    </contact>
    <investigator>
      <last_name>Raza Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Akerley Wallace</last_name>
      <phone>801-585-0255</phone>
    </contact>
    <investigator>
      <last_name>Akerley Wallace, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Michael Boyer</last_name>
      <phone>0011 61 2 8514 0194</phone>
    </contact>
    <investigator>
      <last_name>Michael Boyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Coast Cancer Institute</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Karen Briscoe</last_name>
      <phone>0011 61 2 6656 5733</phone>
    </contact>
    <investigator>
      <last_name>Karen Briscoe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Prunella Blinman</last_name>
      <phone>0011 61 2 9767 5988</phone>
    </contact>
    <investigator>
      <last_name>Prunella Blinman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Douglas</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Suresh Varma</last_name>
      <phone>0011 61 07 4433 3548</phone>
    </contact>
    <investigator>
      <last_name>Suresh Varma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Care</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Keith Horwood</last_name>
      <phone>0011 61 07 5657 6405</phone>
    </contact>
    <investigator>
      <last_name>Keith Horwood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Wolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Ken O'Byrne</last_name>
      <phone>0011 61 07 3176 3962</phone>
    </contact>
    <investigator>
      <last_name>Ken O'Byrne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5043</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Christos Karapetis</last_name>
      <phone>0011 61 08 8204 6151</phone>
    </contact>
    <investigator>
      <last_name>Christos Karapetis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Health</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Phillip Parente</last_name>
      <phone>0011 61 3 9094 9502</phone>
    </contact>
    <investigator>
      <last_name>Phillip Parente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Vinod Ganju</last_name>
      <phone>0011 61 3 9771 8910</phone>
    </contact>
    <investigator>
      <last_name>Vinod Ganju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ballarat Oncology and Haematology</name>
      <address>
        <city>Wendouree</city>
        <state>Victoria</state>
        <zip>3355</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. George Kannourakis</last_name>
      <phone>0011 61 3 5339 8000</phone>
    </contact>
    <investigator>
      <last_name>George Kannourakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Pok Fu Lam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. James C.M. Ho</last_name>
      <phone>852-22554349</phone>
    </contact>
    <investigator>
      <last_name>James C.M. Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO G.Rummo</name>
      <address>
        <city>Benevento</city>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Daniele Bruno</last_name>
      <phone>+39 082457724</phone>
    </contact>
    <investigator>
      <last_name>Daniele Bruno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Barbara Melotti</last_name>
      <phone>+39 0516362203</phone>
    </contact>
    <investigator>
      <last_name>Barbara Melotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale S.Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Luca Gianni</last_name>
      <phone>+39 02-26436531</phone>
    </contact>
    <investigator>
      <last_name>Luca Gianni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Lorenzo Pavesi</last_name>
      <phone>+39 0382592669</phone>
    </contact>
    <investigator>
      <last_name>Lorenzo Pavesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano MI</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Armando Santoro</last_name>
      <phone>+39 0282244080</phone>
    </contact>
    <investigator>
      <last_name>Armando Santoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Treviglio-Caravaggio</name>
      <address>
        <city>Treviglio BG</city>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Sandro Barni</last_name>
      <phone>+39 0363424303</phone>
    </contact>
    <investigator>
      <last_name>Sandro Barni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Chungcheongbuk-do</city>
        <zip>362-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Lee Ki Hyeong</last_name>
      <phone>82-43-269-6905</phone>
    </contact>
    <investigator>
      <last_name>Lee Ki Hyeong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Jeonnam</city>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Kim Joo-Hang</last_name>
      <phone>82-61-379-7614</phone>
    </contact>
    <investigator>
      <last_name>Kim Joo-Hang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei Uni</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Kim Joo-Hang</last_name>
      <phone>82-2-2228-8131</phone>
    </contact>
    <investigator>
      <last_name>Kim Joo-Hang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Park Keunchil</last_name>
      <phone>82-2-3410-3450</phone>
    </contact>
    <investigator>
      <last_name>Park Keunchil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Toh Chee Keong</last_name>
      <phone>+65-6436-8000</phone>
    </contact>
    <investigator>
      <last_name>Toh Chee Keong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 1, 2015</lastchanged_date>
  <firstreceived_date>December 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
